Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors With BRCA1/2 Mutations or Other DDR Deficiencies or High Replication Stress.

NCT07356453 is registered in ClinicalTrials.gov with FoRx Therapeutics AG as lead sponsor.

NCT NCT07356453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07356453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors With BRCA1/2 Mutations or Other DDR Deficiencies or High Replication Stress.
Lead sponsor
FoRx Therapeutics AG
Phase
Phase 1
Overall status
Recruiting
Start date
July 22, 2025
Completion date
April 30, 2028
Enrollment
40 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors